Annals of Hematology

, Volume 96, Issue 9, pp 1563–1568 | Cite as

Calcineurin inhibitor-free GVHD prophylaxis with sirolimus and mycophenolate mofetil combination

Letter to the Editor
First Online:
Received:
Accepted:
This is a preview of subscription content, log in to check access.

Notes

Compliance with ethical standards

All authors acknowledge no financial interests or motives in contribution of the manuscript.

Each author has participated sufficiently in the work to take public responsibility for the content.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).

Informed consent was obtained from all patients for being included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M, Appelbaum FR, Bensinger WI, Buckner CD, Clift RA (1985) Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 65:1325–1334PubMedGoogle Scholar
  2. 2.
    Chao NJ, Schmidt GM, Niland JC, Amylon MD, Dagis AC, Long GD, Nademanee AP, Negrin RS, O’Donnell MR, Parker PM (1993) Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med 329:1225–1230CrossRefPubMedGoogle Scholar
  3. 3.
    Field EH, Matesic D, Rigby S, Fehr T, Rouse T, Gao Q (2001) CD4+CD25+ regulatory cells in acquired MHC tolerance. Immunol Rev 182:99–112CrossRefPubMedGoogle Scholar
  4. 4.
    Kingsley CI, Karim M, Bushell AR, Wood KJ (2002) CD25+CD4+ regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J Immunol (Baltimore, Md : 1950) 168:1080–1086Google Scholar
  5. 5.
    Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, Bellucci R, Alyea EP, Antin JH, Soiffer RJ, Ritz J (2005) Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood 106:2903–2911CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Rezvani K, Mielke S, Ahmadzadeh M, Kilical Y, Savani BN, Zeilah J, Keyvanfar K, Montero A, Hensel N, Kurlander R, Barrett AJ (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108:1291–1297CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Edinger M, Hoffmann P, Ermann J, Drago K, Fathman CG, Strober S, Negrin RS (2003) CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 9:1144–1150CrossRefPubMedGoogle Scholar
  8. 8.
    Coenen JJA, Koenen HJPM, van Rijssen E, Kasran A, Boon L, Hilbrands LB, Joosten I (2007) Rapamycin, not cyclosporine, permits thymic generation and peripheral preservation of CD4+ CD25+ FoxP3+ T cells. Bone Marrow Transplant 39:537–545CrossRefPubMedGoogle Scholar
  9. 9.
    Marty FM, Bryar J, Browne SK, Schwarzberg T, Ho VT, Bassett IV, Koreth J, Alyea EP, Soiffer RJ, Cutler CS, Antin JH, Baden LR (2007) Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood 110:490–500CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R (2012) Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transplant 47:581–588CrossRefPubMedGoogle Scholar
  11. 11.
    Schleuning M, Judith D, Jedlickova Z, Stübig T, Heshmat M, Baurmann H, Schwerdtfeger R (2009) Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant 43:717–723CrossRefPubMedGoogle Scholar
  12. 12.
    Bejanyan N, Rogosheske J, Defor TE, Holtan S, Jacobson P, MacMillan ML, Verneris MR, Arora M, Lazaryan A, Blazar BR, Weisdorf DJ, Wagner JE, Brunstein CG (2016) Sirolimus/mycophenolate mofetil (MMF): effective calcineurin inhibitor-free gvhd prophylaxis for reduced Intensity conditioning (RIC) umbilical cord blood (UCB) transplantation. Biol Blood Marrow Transplant Elsevier 22:S305CrossRefGoogle Scholar
  13. 13.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H-J (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol Off J Am Soc Clin Oncol 23:5675–5687CrossRefGoogle Scholar
  14. 14.
    Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, Antin JH (2007) Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood Am Soc Hematol 109deeg:3108–3114Google Scholar
  15. 15.
    Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ (2003) Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102:1601–1605CrossRefPubMedGoogle Scholar
  16. 16.
    Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R (2008) Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 112:4425–4431CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, Stoehlmacher J, Schetelig J, Thiede C, Ehninger G, Bornhäuser M (2009) Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 15:101–108CrossRefGoogle Scholar
  18. 18.
    Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, de Oteiza JP, Duarte R, Carella AM, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Bonifazi F (2016) Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med 374:43–53CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  1. 1.Department of Medicine, Division of Hematology/Oncology, Bone Marrow TransplantUniversity of Massachusetts Medical Center and Medical SchoolWorcesterUSA
  2. 2.Bone Marrow TransplantBanner MD Anderson Cancer CenterGilbertUSA

Personalised recommendations